{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:46Z","timestamp":1785269926072,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obsessive-Compulsive Disorder (OCD) can present significant challenges to individuals mental health, characterized by intrusive thoughts and repetitive maladaptive behaviors. Recent research into alternative treatments has highlighted psychedelics, notably psilocybin, for their potential therapeutic benefits in various psychiatric disorders, including OCD. This case study evaluated the impact of self-administered, low-doses of psilocybin, commonly referred to as microdosing, on symptom reduction and cognitive flexibility in OCD, with a focus on identical twins discordant for the condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      The study documents the experiences of one twin diagnosed with OCD who began a regimen of low-doses of psilocybin containing mushrooms, while the other twin, unaffected by OCD, served as a comparison. Case X was diagnosed with OCD by a general practitioner in the Danish healthcare system. Following years of severe OCD, case X began a self-medicated regimen consisting of psilocybin containing mushrooms, corresponding to 1\u20135 mg of psilocybin, every 3\n                      <jats:sup>rd<\/jats:sup>\n                      day. The other twin, case Y, who remained unaffected by OCD, and did not take psilocybin containing mushrooms. Cognitive flexibility was evaluated in both cases using a set-shift task. The affected twin reported a notable reduction in OCD symptoms, along with improvements in emotional regulation and overall well-being. However, despite these symptomatic improvements, deficits in cognitive flexibility remained present compared to the unaffected twin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case study underscores the potential of low-doses of psilocybin as a promising avenue for mitigating symptoms of OCD. Nevertheless, the observed disparity in cognitive flexibility highlights the nuanced nature of OCD pathology, suggesting that while low-doses of psilocybin may alleviate certain symptoms, it may not fully address underlying cognitive impairments. Further research employing larger sample sizes and rigorous longitudinal designs is imperative to elucidate the mechanisms underlying the therapeutic effects of psilocybin low-doses in OCD, offering insights into its broader applicability as a treatment modality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1819962","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:34:39Z","timestamp":1776749679000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins"],"prefix":"10.3389","volume":"17","author":[{"given":"Sivert","family":"Drange","sequence":"first","affiliation":[{"name":"Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark","place":["Odense, Denmark"]},{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Cohen","sequence":"additional","affiliation":[{"name":"Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark","place":["Odense, Denmark"]},{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]},{"name":"The Hospital for Sick Children","place":["Toronto, ON, Canada"]},{"name":"Department of Pharmacology and Toxicology, University of Toronto","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sys Stybe","family":"Johansen","sequence":"additional","affiliation":[{"name":"Section of Forensic Chemistry, Department of Forensic Medicine, Faculty of Health and Medical Sciences, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Dunkley","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Palner","sequence":"additional","affiliation":[{"name":"Clinical Physiology and Nuclear Medicine, Department of Clinical Research, University of Southern Denmark","place":["Odense, Denmark"]},{"name":"Department of Nuclear Medicine, Odense University Hospital","place":["Odense, Denmark"]},{"name":"Neurobiology Research Unit, Copenhagen University Hospital","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","first-page":"1","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","article-title":"Obsessive\u2013compulsive disorder","volume":"5","author":"Stein","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2035\u201343","DOI":"10.1007\/s00127-012-0507-8","article-title":"Obsessive--compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial Asian population","volume":"47","author":"M","year":"2012","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"783\u20138","DOI":"10.1176\/ajp.153.6.783","article-title":"Quality of life for patients with obsessive-compulsive disorder","volume":"153","author":"Lm","year":"1996","journal-title":"Am J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21\u20133","DOI":"10.1017\/S1092852912000697","article-title":"Quality of life in obsessive compulsive disorder","volume":"18","author":"As","year":"2013","journal-title":"CNS Spectr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: Advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v03n0105","article-title":"SSRI antidepressant medications: Adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Comp J Clin Psychiatry"},{"key":"B8","unstructured":"Mental illness - national institute of mental health (NIMH)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-psych-113011-143750","article-title":"Executive functions","volume":"64","author":"Diamond","year":"2013","journal-title":"Annu Rev Psychol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.7.1282","article-title":"Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania","volume":"163","author":"Chamberlain","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.11.1225","article-title":"Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder","volume":"63","author":"Remijnse","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.07.030","article-title":"Cognitive inflexibility in obsessive-compulsive disorder","volume":"345","author":"Gruner","year":"2017","journal-title":"Neuroscience"},{"key":"B13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder","volume":"11","author":"Doss","year":"2021","journal-title":"Transl Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01545-z","article-title":"Acute psilocybin enhances cognitive flexibility in rats","volume":"48","author":"Torrado Pacheco","year":"2023","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"426\u201334","DOI":"10.1177\/28314425251386879","article-title":"Computational analysis of psilocybin effects on three-choice touchscreen reversal learning in rats: A pilot study","volume":"22","author":"Gregersen","year":"2026","journal-title":"Psy Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13741","article-title":"Impact of psilocybin on cognitive function: A systematic review","volume":"78","author":"Meshkat","year":"2024","journal-title":"Psychiatry Clin Neurosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacol Berl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00672","article-title":"Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers","volume":"10","author":"Hutten","year":"2019","journal-title":"Front Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.1038\/s41598-022-14512-3","article-title":"Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls","volume":"12","author":"Rootman","year":"2022","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1278823","article-title":"Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings","volume":"14","author":"Ching","year":"2023","journal-title":"Front Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.7.1037b","article-title":"Hallucinogen-induced relief of obsessions and compulsions","volume":"154","author":"Moreno","year":"1997","journal-title":"Am J Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2020.1849879","article-title":"Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms","volume":"53","author":"Lugo-Radillo","year":"2021","journal-title":"J Psy Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1977.tb00149.x","article-title":"LSD treatment in a severe case of compulsive neurosis","volume":"55","author":"Brandrup","year":"1977","journal-title":"Acta Psychiatr Scand"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e12135","article-title":"Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report","volume":"8","author":"Kelmendi","year":"2022","journal-title":"Heliyon"},{"key":"B26","doi-asserted-by":"publisher","first-page":"77\u201387","DOI":"10.1556\/2054.2020.00128","article-title":"A potential role for psilocybin in the treatment of obsessive-compulsive disorder","volume":"4","author":"Jacobs","year":"2020"},{"key":"B27","doi-asserted-by":"publisher","first-page":"911\u201325","DOI":"10.1007\/s43440-024-00633-1","article-title":"Psilocybin in pharmacotherapy of obsessive-compulsive disorder","volume":"76","author":"Owe-Larsson","year":"2024","journal-title":"Pharmacol Rep Pr"},{"key":"B28","article-title":"Therapeutic effect of psilocybin on convulsive neurosis","volume":"117","author":"Delay","year":"1959","journal-title":"Ann Med Psychol Paris"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2014.963754","article-title":"Psilocybin and obsessive compulsive disorder","volume":"46","author":"Wilcox","year":"2014","journal-title":"J Psy Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.47626\/1516-4446-2025-4316","article-title":"Real-world use of classic and non-classic psychedelics in Hispanic\/Latino adults with obsessive-compulsive disorder: International findings from the LATINO Study","author":"Mathai","year":"2025","journal-title":"Rev Bras Psiquiatr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2025.152619","article-title":"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study","volume":"142","author":"Pellegrini","year":"2025","journal-title":"Compr Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2025.10895","article-title":"Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study","volume":"12","author":"Ledwos","year":"2025","journal-title":"BJPsych Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2698811261424214","DOI":"10.1177\/02698811261424214","article-title":"A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder","author":"Moreno","year":"2026","journal-title":"J Psychopharmacol Oxf"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1726818","article-title":"Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis","volume":"16","author":"Ching","year":"2025","journal-title":"Front Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"6","author":"Moreno","year":""},{"key":"B36","doi-asserted-by":"crossref","unstructured":"Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles\n          \n          \n            \n              Baumeister\n              D\n            \n            \n              Barnes\n              G\n            \n            \n              Giaroli\n              G\n            \n            \n              Tracy\n              D\n            \n          \n          10.1177\/2045125314527985\n          25083275\n          Ther Adv Psychopharmacol.\n          4\n          2014","DOI":"10.1177\/2045125314527985"},{"key":"B37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41398-023-02456-9","article-title":"Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder","volume":"13","author":"Singh","year":"2023","journal-title":"Transl Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02786-0","article-title":"Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming","volume":"30","author":"Brownstien","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2014.12.003","article-title":"Obsessive\u2013compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults","volume":"227","author":"Fineberg","year":"2015","journal-title":"Psychiatry Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000075","article-title":"A contemporary psychometric evaluation of the obsessive compulsive inventory \u2013 revised (OCI-R)","volume":"27","author":"Wootton","year":"2015","journal-title":"Psychol Assess"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1400","article-title":"Magic truffles or philosopher\u2019s stones: a legal way to sell psilocybin","volume":"5","author":"Pellegrini","year":"2013","journal-title":"Drug Test Anal"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00823-4","article-title":"Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin","volume":"46","author":"Madsen","year":"2021","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bandc.2009.03.005","article-title":"The Wisconsin card sorting test and the cognitive assessment of prefrontal executive functions: a critical update","volume":"71","author":"Nyhus","year":"2009","journal-title":"Brain Cognit"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10519-009-9262-3","article-title":"A twin study of the genetics of high cognitive ability selected from 11,000 twin pairs in six studies from four countries","volume":"39","author":"Haworth","year":"2009","journal-title":"Behav Genet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320950567","article-title":"The therapeutic potential of microdosing psychedelics in depression","volume":"10","author":"Kuypers","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"00221678221075076","DOI":"10.1177\/00221678221075076","article-title":"Microdosing as a response to the meaning crisis: a qualitative analysis","author":"Petranker","year":"2022","journal-title":"J Hum Psychol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","article-title":"Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study","volume":"12","author":"Cavanna","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/02698811231179801","article-title":"Psilocybin\u2019s effects on cognition and creativity: a scoping review","volume":"37","author":"Bonnieux","year":"2023","journal-title":"J Psychopharmacol Oxf Engl"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1819962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:34:46Z","timestamp":1776749686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1819962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":48,"alternative-id":["10.3389\/fpsyt.2026.1819962"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1819962","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1819962"}}